Svas Biosana S.p.A.

As of December 31, 2025, Svas Biosana S.p.A. carries a market capitalization of 41.89M, placing it among publicly traded companies globally. Its enterprise value stands at 96.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Svas Biosana S.p.A.'s next confirmed earnings release is scheduled for April 20, 2027.

As of December 31, 2025, Svas Biosana S.p.A. has 5.24M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Svas Biosana S.p.A. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Svas Biosana S.p.A.'s stock has declined approximately 13.26% over the past 52 weeks. The 50-day moving average sits at 8.03, while the 200-day moving average is 8.61.

As of December 31, 2025, Svas Biosana S.p.A. holds 24.15M in cash and equivalents against 78.48M in total debt, resulting in a net debt position of 54.43M. Total book value stands at 67.39M, with working capital of 62.93M providing operational flexibility.